Hologic beats Q2 guidance; raises FY2024 revenue & EPS outlook; acquires Endomagnetics for $310M

HOLOGIC INC

2024-Q2 EPS reported $1.74 revenue$2,030,900,000

Revenue $1,017.8M (-0.8% YoY); GAAP EPS $0.72, Non-GAAP EPS $1.03, both above guidance.
Organic revenue ex-COVID grew 4.9% constant currency; Diagnostics ex-COVID +9.8%, Surgical +7.7%.
Raised FY2024 revenue midpoint (constant currency) and EPS guidance on strong margins.
Agreed to acquire Endomagnetics Ltd for ~$310M to expand interventional breast business.
Operating cash flow $292.4M in Q2; cash flow from operations remains strong.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HOLOGIC INC reported fiscal second quarter ended March 30, 2024 results: revenue $1,017.8 million, EPS GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03. Guidance raised.

Period: fiscal second quarter ended March 30, 2024
Revenue: $1,017.8 million
EPS: GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03
Guidance: raised
Result: reported results

Exact text from the filing

Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03

View on SEC.gov

201 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001140361-24-023989

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.